Entering text into the input field will update the search result below

FDA accepts Acorda's marketing application for Parkinson's med Inbrija, action date October 5

Feb. 20, 2018 12:47 PM ETAcorda Therapeutics, Inc. (ACOR) StockBy: Douglas W. House, SA News Editor
  • The FDA accepts for review Acorda Therapeutics' (NASDAQ:ACOR -0.8%) refiled New Drug Application (NDA) seeking approval for inhaled INBRIJA (levodopa) for the treatment of OFF periods in Parkinson's disease (PD) patients currently on a carbidopa/levodopa regimen. The agency's action date is October 5.
  • An OFF period is when PD symptoms reappear when the efficacy of medications wanes or before the patient takes the next dose of levodopa.
  • Previously: Acorda refiles U.S. marketing application for Parkinson's med Inbrija; shares up 5% premarket (Dec. 7, 2017)

Recommended For You

More Trending News

About ACOR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ACOR--
Acorda Therapeutics, Inc.